28 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Delirium in the ICU

Defining delirium
Types of delirium
Consequences of delirium
Reversible causes of delirium
Drug-induced delirium
Non-pharmacologic management of delirium
Pharmacologic
Delirium in the ICU ... delirium Reversible causes ... Pharmacologic ... management of delirium ... theABofPharmaC #ICU
Pain, Agitation, and Delirium (PAD) in the ICU
Addressing the ICU Triad (PAD) can be accomplished through
it should not cause ... dissociative drug, it causes ... No pharmacologic ... (Haldol) - No pharmacologic ... CriticalCare #diagnosis #management
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
• In rare cases ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology